Alnylam Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Alnylam Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76% to $1,828,292,000. The net income raised on -$440,242,000 and profit margin reached -24%. Total operating expenses were $1,800,061,000.
Profit Margin
| 2014 | 50.56M | -360.39M | -712.79% |
|---|---|---|---|
| 2015 | 41.09M | -290.07M | -705.83% |
| 2016 | 47.15M | -410.10M | -869.63% |
| 2017 | 89.91M | -490.87M | -545.95% |
| 2018 | 74.90M | -761.49M | -1016.58% |
| 2019 | 219.75M | -886.11M | -403.24% |
| 2020 | 492.85M | -858.28M | -174.15% |
| 2021 | 844.28M | -852.82M | -101.01% |
| 2022 | 1.03B | -1.13B | -109.04% |
| 2023 | 1.82B | -440.24M | -24.08% |
ALNY Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 1.82B | 1.03B | 844.28M | 492.85M | 219.75M | 74.90M | 89.91M | 47.15M | 41.09M | 50.56M |
Cost of revenue | 310.40M | 168.81M | 140.14M | 78.05M | 25.06M | 1.80M | 13.36M | 0 | 0 | 0 |
Gross profit | 1.51B | 868.60M | 704.14M | 414.80M | 194.68M | 73.10M | 76.54M | 47.15M | 41.09M | 50.56M |
Operating exp. | ||||||||||
Research and development | 1.00B | 883.01M | 792.15M | 654.81M | 655.11M | 505.42M | 390.63M | 382.39M | 276.49M | 190.24M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 1.80B | 1.65B | 1.41B | 1.24B | 1.13B | 887.77M | 590M | 471.74M | 337.10M | 234.77M |
Operating income | -282.17M | -785.07M | -708.65M | -828.43M | -939.43M | -814.67M | -500.08M | -424.58M | -296.00M | -404.98M |
Other income (expenses), net | -151.34M | -341.92M | -143.49M | -27.16M | 54.17M | 24.73M | 9.21M | 6.17M | 5.93M | 4.37M |
Income before tax | -433.51M | -1.12B | -852.14M | -855.6M | -885.25M | -760.67M | -490.87M | -410.10M | -290.07M | -400.60M |
Income tax expense | 6.72M | 4.16M | 680K | 2.68M | 863K | 823K | -25.60M | -23.43M | -24.90M | -40.20M |
Net income | -440.24M | -1.13B | -852.82M | -858.28M | -886.11M | -761.49M | -490.87M | -410.10M | -290.07M | -360.39M |
Earnings per share | ||||||||||
Basic EPS | -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 |
Diluted EPS | -3.52 | -9.3 | -7.2 | -7.46 | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 | -4.85 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |